Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 2/2019

17.10.2018 | Original Article

Should Pyloric Lymph Nodes Be Dissected for Siewert Type II and III Adenocarcinoma of the Esophagogastric Junctions: Experience from a High-Volume Center in China

verfasst von: Huihua Cao, Marie Ooi, Zhan Yu, Qing Wang, Zhong Li, Qicheng Lu, Yugang Wu

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The optimal extent of lymph node (LN) dissection remains controversial in adenocarcinoma of the esophagogastric junction (AEG), especially in Siewert types II and III. The aim of this study was to analyze clinicopathological characteristics of patients with Siewert type II and III AEGs to clarify whether pyloric (no. 5 and no.6) lymphadenectomy is essential in these patients.

Methods

A retrospective analysis was performed in the Third Affiliated Hospital of Soochow University from September 2008 to December 2012, and clinicopathological characteristics on all patients with Siewert type II and III AEGs, who underwent curative total gastrectomy with lymphadenectomy were collected. The index of estimated benefit from lymph node dissection (IEBLD) was used to evaluate the efficacy of lymph node dissection of no. 5 and no. 6. Both clinicopathological characteristics and IEBLDs were set as the standards in the assessment of the value of pyloric lymph nodes dissection.

Results

A total of 216 patients with AEG (Siewert type II: 141, Siewert type III: 75) were included into the study. Type III AEG had a larger tumor size and relatively advanced T stage compared to Type II AEG. The 5-year overall survival (OS) rates in type II and type III AEGs were almost similar (type II 50.4% vs. type III 46.7%, p = 0.782). There was a very low incidence of pyloric lymph nodes metastases in type II AEG (no. 5 is 1.4% and no. 6 is 0.7%). Hence, the IEBLDs of no. 5 and no. 6 lymph node were negligible regardless of the T stage and tumor differentiation. In type III AEG, metastasis rates of no. 5 and no. 6 lymph node were 9.3 and 5.3%, respectively. The IEBLDs of no. 5 and no. 6 lymph node were 2.7 and 1.3, respectively.

Conclusions

Based on the IEBLDs of pyloric lymph nodes, dissection of no. 5 and no. 6 lymph nodes were worthwhile for Siewert type III AEG but not essential for Siewert type II AEG.
Literatur
1.
Zurück zum Zitat Goto H, Tokunaga M, Miki Y, Makuuchi R, Sugisawa N, Tanizawa Y, Bando E, Kawamura T, Niihara M, Tsubosa Y, Terashima M. The optimal extent of lymph node dissection for adenocarcinoma of the esophagogastric junction differs between Siewert type II and Siewert type III patients. Gastric cancer 2015;18:375–381.CrossRef Goto H, Tokunaga M, Miki Y, Makuuchi R, Sugisawa N, Tanizawa Y, Bando E, Kawamura T, Niihara M, Tsubosa Y, Terashima M. The optimal extent of lymph node dissection for adenocarcinoma of the esophagogastric junction differs between Siewert type II and Siewert type III patients. Gastric cancer 2015;18:375–381.CrossRef
2.
Zurück zum Zitat Xiao JW, Liu ZL, Ye PC, Luo YJ, Fu ZM, Zou Q, Wei SJ. Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction. World journal of gastroenterology 2015;21:9999–10007.CrossRefPubMedPubMedCentral Xiao JW, Liu ZL, Ye PC, Luo YJ, Fu ZM, Zou Q, Wei SJ. Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction. World journal of gastroenterology 2015;21:9999–10007.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Lee IS, Ahn JY, Yook JH, Kim BS. Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma. World journal of surgical oncology 2017;15:28.CrossRefPubMedPubMedCentral Lee IS, Ahn JY, Yook JH, Kim BS. Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma. World journal of surgical oncology 2017;15:28.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Rudiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Annals of surgery 2000;232:353–361.CrossRefPubMedPubMedCentral Rudiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Annals of surgery 2000;232:353–361.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Kodera Y, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K, Morimoto T, Kato T. Adenocarcinoma of the gastroesophageal junction in Japan: relevance of Siewert's classification applied to 177 cases resected at a single institution. Journal of the American College of Surgeons 1999;189:594–601.CrossRefPubMed Kodera Y, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K, Morimoto T, Kato T. Adenocarcinoma of the gastroesophageal junction in Japan: relevance of Siewert's classification applied to 177 cases resected at a single institution. Journal of the American College of Surgeons 1999;189:594–601.CrossRefPubMed
6.
Zurück zum Zitat Brenkman HJF, Roelen SVS, Steenhagen E, Ruurda JP, van Hillegersberg R. Postoperative complications and weight loss following jejunostomy tube feeding after total gastrectomy for advanced adenocarcinomas. Chinese journal of cancer research 2017;29:333–340.CrossRefPubMedPubMedCentral Brenkman HJF, Roelen SVS, Steenhagen E, Ruurda JP, van Hillegersberg R. Postoperative complications and weight loss following jejunostomy tube feeding after total gastrectomy for advanced adenocarcinomas. Chinese journal of cancer research 2017;29:333–340.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Bae JM, Park JW, Yang HK, Kim JP. Nutritional status of gastric cancer patients after total gastrectomy. World journal of surgery 1998;22:254–260.CrossRefPubMed Bae JM, Park JW, Yang HK, Kim JP. Nutritional status of gastric cancer patients after total gastrectomy. World journal of surgery 1998;22:254–260.CrossRefPubMed
8.
Zurück zum Zitat Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. The British journal of surgery 1995;82:346–351.CrossRefPubMed Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. The British journal of surgery 1995;82:346–351.CrossRefPubMed
9.
Zurück zum Zitat Ilhan E, Ureyen O, Meral UM. Ongoing problems concerning 7(th) TNM staging system and proposals for 8(th) TNM staging system of gastric cancer. Przeglad gastroenterologiczny 2016;11:223–225.PubMedPubMedCentral Ilhan E, Ureyen O, Meral UM. Ongoing problems concerning 7(th) TNM staging system and proposals for 8(th) TNM staging system of gastric cancer. Przeglad gastroenterologiczny 2016;11:223–225.PubMedPubMedCentral
10.
Zurück zum Zitat Hasegawa S, Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O. Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center. World journal of surgery 2009;33:95–103.CrossRefPubMed Hasegawa S, Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O. Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center. World journal of surgery 2009;33:95–103.CrossRefPubMed
11.
Zurück zum Zitat Chen XZ, Zhang WH, Hu JK. Lymph node metastasis and lymphadenectomy of resectable adenocarcinoma of the esophagogastric junction. Chinese journal of cancer research 2014;26:237–242.PubMedPubMedCentral Chen XZ, Zhang WH, Hu JK. Lymph node metastasis and lymphadenectomy of resectable adenocarcinoma of the esophagogastric junction. Chinese journal of cancer research 2014;26:237–242.PubMedPubMedCentral
12.
Zurück zum Zitat Carboni F, Valle M, Federici O, Levi Sandri GB, Camperchioli L, Lapenta R, Assisi D, Garofalo A. Esophagojejunal anastomosis leakage after total gastrectomy for esophagogastric junction adenocarcinoma: options of treatment. Journal of gastrointestinal oncology 2016;7:515–522.CrossRefPubMedPubMedCentral Carboni F, Valle M, Federici O, Levi Sandri GB, Camperchioli L, Lapenta R, Assisi D, Garofalo A. Esophagojejunal anastomosis leakage after total gastrectomy for esophagogastric junction adenocarcinoma: options of treatment. Journal of gastrointestinal oncology 2016;7:515–522.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Aday U, Gundes E, Ciyiltepe H, Cetin DA, Gulmez S, Senger AS, Deger KC, Duman M. Examination of anastomotic leak with aqueous contrast swallow after total gastrectomy: should it be carried out routinely? Contemporary oncology 2017;21:224–227.PubMedPubMedCentral Aday U, Gundes E, Ciyiltepe H, Cetin DA, Gulmez S, Senger AS, Deger KC, Duman M. Examination of anastomotic leak with aqueous contrast swallow after total gastrectomy: should it be carried out routinely? Contemporary oncology 2017;21:224–227.PubMedPubMedCentral
14.
Zurück zum Zitat Huh YJ, Lee HJ, Oh SY, Lee KG, Yang JY, Ahn HS, Suh YS, Kong SH, Lee KU, Yang HK. Clinical outcome of modified laparoscopy-assisted proximal gastrectomy compared to conventional proximal gastrectomy or total gastrectomy for upper-third early gastric cancer with special references to postoperative reflux esophagitis. Journal of gastric cancer 2015;15:191–200.CrossRefPubMedPubMedCentral Huh YJ, Lee HJ, Oh SY, Lee KG, Yang JY, Ahn HS, Suh YS, Kong SH, Lee KU, Yang HK. Clinical outcome of modified laparoscopy-assisted proximal gastrectomy compared to conventional proximal gastrectomy or total gastrectomy for upper-third early gastric cancer with special references to postoperative reflux esophagitis. Journal of gastric cancer 2015;15:191–200.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Katsoulis IE, Robotis JF, Kouraklis G, Yannopoulos PA. What is the difference between proximal and total gastrectomy regarding postoperative bile reflux into the oesophagus? Digestive surgery 2006;23:325–330.CrossRefPubMed Katsoulis IE, Robotis JF, Kouraklis G, Yannopoulos PA. What is the difference between proximal and total gastrectomy regarding postoperative bile reflux into the oesophagus? Digestive surgery 2006;23:325–330.CrossRefPubMed
16.
Zurück zum Zitat Ahn HS, Lee HJ, Yoo MW, Jeong SH, Park DJ, Kim HH, Kim WH, Lee KU, Yang HK. Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. The British journal of surgery 2011;98:255–260.CrossRefPubMed Ahn HS, Lee HJ, Yoo MW, Jeong SH, Park DJ, Kim HH, Kim WH, Lee KU, Yang HK. Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. The British journal of surgery 2011;98:255–260.CrossRefPubMed
17.
Zurück zum Zitat Pu YW, Gong W, Wu YY, Chen Q, He TF, Xing CG. Proximal gastrectomy versus total gastrectomy for proximal gastric carcinoma. A meta-analysis on postoperative complications, 5-year survival, and recurrence rate. Saudi medical journal 2013;34:1223–1228.PubMed Pu YW, Gong W, Wu YY, Chen Q, He TF, Xing CG. Proximal gastrectomy versus total gastrectomy for proximal gastric carcinoma. A meta-analysis on postoperative complications, 5-year survival, and recurrence rate. Saudi medical journal 2013;34:1223–1228.PubMed
18.
Zurück zum Zitat Nunobe S, Hiki N. Function-preserving surgery for gastric cancer: current status and future perspectives. Translational gastroenterology and hepatology 2017;2:77.CrossRefPubMedPubMedCentral Nunobe S, Hiki N. Function-preserving surgery for gastric cancer: current status and future perspectives. Translational gastroenterology and hepatology 2017;2:77.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Aratani K, Komatsu S, Ichikawa D, et al. Overexpression of EGFR as an independent prognostic factor in adenocarcinoma of the esophagogastric junction. Anticancer Res 2017;37:3129–3135.PubMed Aratani K, Komatsu S, Ichikawa D, et al. Overexpression of EGFR as an independent prognostic factor in adenocarcinoma of the esophagogastric junction. Anticancer Res 2017;37:3129–3135.PubMed
20.
Zurück zum Zitat Hosoda K, Yamashita K, Moriya H, Mieno H, Watanabe M. Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: a retrospective cohort study with long-term follow-up. World Journal of Gastroenterology 2017;23:2723–2730.CrossRefPubMedPubMedCentral Hosoda K, Yamashita K, Moriya H, Mieno H, Watanabe M. Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: a retrospective cohort study with long-term follow-up. World Journal of Gastroenterology 2017;23:2723–2730.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Annals of surgery 2011;254:274–280.CrossRefPubMed Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Annals of surgery 2011;254:274–280.CrossRefPubMed
22.
Zurück zum Zitat Fujitani K, Miyashiro I, Mikata S, Tamura S, Imamura H, Hara J, Kurokawa Y, Fujita J, Nishikawa K, Kimura Y, Takiguchi S, Mori M, Doki Y. Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type II adenocarcinoma of the cardia: results of a multicenter study. Gastric Cancer 2013;16:301–308.CrossRefPubMed Fujitani K, Miyashiro I, Mikata S, Tamura S, Imamura H, Hara J, Kurokawa Y, Fujita J, Nishikawa K, Kimura Y, Takiguchi S, Mori M, Doki Y. Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type II adenocarcinoma of the cardia: results of a multicenter study. Gastric Cancer 2013;16:301–308.CrossRefPubMed
23.
Zurück zum Zitat Miwa K, Kinami S, Taniguchi K, Fushida S, Fujimura T, Nonomura A. Mapping sentinel nodes in patients with early-stage gastric carcinoma. The British Journal Of Surgery 2003;90:178–182.CrossRefPubMed Miwa K, Kinami S, Taniguchi K, Fushida S, Fujimura T, Nonomura A. Mapping sentinel nodes in patients with early-stage gastric carcinoma. The British Journal Of Surgery 2003;90:178–182.CrossRefPubMed
24.
Zurück zum Zitat Shen KR, Cassivi SD, Deschamps C, Allen MS, Nichols FC, Harmsen WS, Pairolero PC. Surgical treatment of tumors of the proximal stomach with involvement of the distal esophagus: a 26-year experience with Siewert type III tumors. The Journal of Thoracic and Cardiovascular Surgery 2006;132:755–762.CrossRefPubMed Shen KR, Cassivi SD, Deschamps C, Allen MS, Nichols FC, Harmsen WS, Pairolero PC. Surgical treatment of tumors of the proximal stomach with involvement of the distal esophagus: a 26-year experience with Siewert type III tumors. The Journal of Thoracic and Cardiovascular Surgery 2006;132:755–762.CrossRefPubMed
25.
Zurück zum Zitat Mocellin S, McCulloch P, Kazi H, Gama-Rodrigues JJ, Yuan Y, Nitti D. Extent of lymph node dissection for adenocarcinoma of the stomach. The Cochrane Database of Systematic Reviews 2015;Cd001964. Mocellin S, McCulloch P, Kazi H, Gama-Rodrigues JJ, Yuan Y, Nitti D. Extent of lymph node dissection for adenocarcinoma of the stomach. The Cochrane Database of Systematic Reviews 2015;Cd001964.
Metadaten
Titel
Should Pyloric Lymph Nodes Be Dissected for Siewert Type II and III Adenocarcinoma of the Esophagogastric Junctions: Experience from a High-Volume Center in China
verfasst von
Huihua Cao
Marie Ooi
Zhan Yu
Qing Wang
Zhong Li
Qicheng Lu
Yugang Wu
Publikationsdatum
17.10.2018
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 2/2019
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-018-3935-2

Weitere Artikel der Ausgabe 2/2019

Journal of Gastrointestinal Surgery 2/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.